Microbio (4128) reported revenue of NT$169.6 million for Oct 2026, -3.1% year on year and +12.7% from the previous month. Revenue for Jan–Oct 2026 was NT$1.61 billion (+3.1% year on year).
In Oct 2026, it ranked No. 48 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$169.6 million | -3.1% | +12.7% |
| Sep 2026 | NT$150.4 million | -6.5% | -2.6% |
| Aug 2026 | NT$154.5 million | -1.3% | +1.6% |
| Jul 2026 | NT$152 million | -2.8% | -5.6% |
| Jun 2026 | NT$161.1 million | +11.9% | +1.8% |
| May 2026 | NT$158.3 million | +4.1% | -1.0% |
| Apr 2026 | NT$159.9 million | +1.8% | -5.8% |
| Mar 2026 | NT$169.6 million | +7.7% | +11.6% |
| Feb 2026 | NT$152 million | +14.0% | -15.6% |
| Jan 2026 | NT$180 million | +8.7% | +9.5% |
| Dec 2025 | NT$164.4 million | +5.9% | -4.0% |
| Nov 2025 | NT$171.2 million | +8.1% | -2.2% |
| Oct 2025 | NT$175 million | +8.6% | +8.8% |
| Sep 2025 | NT$160.8 million | +10.2% | +2.7% |
| Aug 2025 | NT$156.5 million | +8.7% | +0.0% |
| Jul 2025 | NT$156.5 million | +13.0% | +8.6% |
| Jun 2025 | NT$144.1 million | +14.4% | -5.2% |
| May 2025 | NT$152 million | +10.4% | -3.2% |
| Apr 2025 | NT$157.1 million | +9.4% | -0.2% |
| Mar 2025 | NT$157.5 million | +8.3% | +18.1% |
| Feb 2025 | NT$133.4 million | +5.9% | -19.5% |
| Jan 2025 | NT$165.6 million | +17.3% | +6.7% |
| Dec 2024 | NT$155.3 million | +12.8% | -1.9% |
| Nov 2024 | NT$158.4 million | +9.1% | -1.7% |
| Oct 2024 | NT$161.2 million | +6.7% | +10.4% |
Jan–Oct 2026 cumulative: NT$1.61 billion (+3.1% YoY)
Other Biotech & Medical companies
Compare with peers: Microbio vs PEC / Microbio vs Lotus Pharm / Microbio vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16